Winst gevend schreef op 2 december 2025 12:54:
.
.
Kalvista Pharmaceuticals matige start voor EkterlyGiven the successful launch of EKTERLY,
oral treatment is attracting strong demand and rapid adoption
among physicians and individuals with HAE.
The therapy has already attracted 937 start forms covering
about 8% of the people diagnosed with HAE in the US.
The company has already launched EKTERLY in Germany,
with approval in Australia, bringing the total number of regulatory approvals to five.